Sector News

Lilly pens deal for Evotec spinout’s immune tolerance drugs

August 22, 2017
Life sciences

Eli Lilly has secured an option on immune tolerance drugs from Evotec spinout Topas Therapeutics. The multiyear agreement positions Lilly to work with Topas on candidates that convey tolerance to antigens linked to inflammation or autoimmune diseases.

Topas will run preclinical proof-of-concept studies of the drugs in collaboration with Lilly in return for R&D funding. Lilly has the option to license and further develop all drug candidates generated in the collaboration. Beyond that, the publicly known details get hazy, with Topas only saying it will “participate in the future success of any compounds in-licensed by Lilly.”

Whatever the terms, the agreement is an early validation of the nanoparticle platform that CRO Evotec saw as sufficiently promising to support a standalone biotech. Topas spun out of Evotec last year, picking up €14 million ($16 million) from its parent company and other investors along the way. The Lilly agreement marks the first time a big pharma has talked up the platform.

“Topas has a very novel approach to immune tolerance induction, which we would like to see successfully applied to certain disease relevant antigens,” Lilly SVP Thomas Bumol, Ph.D., said in a statement.

Hamburg, Germany-based Topas is built on a platform Evotec picked up from academic centers in its home country. The platform produces nanoparticles loaded with disease-relevant peptides. The endosomal compartments of liver sinusoidal endothelial cells take up the drugs and present the antigenic peptides to T cells, triggering the induction of anti-inflammatory regulatory T cells. In animal models, one intravenous dose of nanoparticles results in immune tolerance.

Topas has applied the platform internally to conditions including multiple sclerosis, type 1 diabetes and celiac disease. The multiple sclerosis program is the most advanced and will serve as a proving ground for the company. Topas penciled in a 2017 move into the clinic when it spun out of Evotec.

The approach and indications pursued by Topas overlap with those of other companies in the emerging immune tolerance sector, some of which have been similarly successful in attracting the interest of larger partners.

Parvus Therapeutics is developing nanoparticles designed to cause the expansion of regulatory T cells and landed a deal with Novartis on the back of its work in type 1 diabetes. And Anokion gave Celgene a buyout option after its approach to immune tolerance turned heads at the prolific dealmaker.

By Nick Paul Taylor

Source: Fierce Biotech

comments closed

Related News

October 2, 2022

GSK names Julie Brown, a 25-year AstraZeneca veteran, its first woman CFO

Life sciences

Five years ago, GSK made headlines when it hired Emma Walmsley to become the first woman to run a major pharmaceutical company. Now the Big Pharma has brought in another woman to control the company’s finances. Julie Brown will be GSK’s next chief financial officer. Brown, currently the chief operating and financial officer at fashion and beauty brand Burberry Group, is set to replace Iain Mackay.

October 2, 2022

Moderna creates new launch preparation role, poaches Novartis exec as manufacturing lead

Life sciences

Moderna created a new role responsible for “building out the company’s organization to support its growing pipeline.” Starting first thing 2023, Juan Andres, Moderna’s manufacturing head, will step into this new role under the title president of strategic partnerships and enterprise expansion, the company said Thursday.

October 2, 2022

Torrent Pharma to acquire Curatio for $245.16m

Life sciences

The latest takeover is anticipated to boost the presence of Torrent in the dermatology segment. Indian company Torrent Pharmaceuticals has signed a definitive agreement for the complete acquisition of Curatio Healthcare for $245.16m (Rs20bn).